Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 22 May 2018 2:09 PM | Hawk Tran (Administrator)

    FY18 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/funding/arp

    Clinical Trial Award – Preapplication due July 5, 2018

    • Investigators at or above the level of Associate Professor (or equivalent), or
    • Early-Career Investigator Partnering PI Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:
    • Must be in a current postdoctoral training position or have completed postdoctoral training by the  application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • Has the freedom to commit at least 50% time to the project
    • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
    • Applications in the following areas are strongly encouraged:
      • Behavioral cognitive, and other non-pharmacological therapies.
      • Pharmacological, genetic, and other biological treatments in ASD.
      • Dissemination/Implementation of clinically validated interventions.
      • Therapies to alleviate conditions co-occurring with ASD (i.e., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures).
      • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
      • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
      • Improve diagnosis across the lifespan.
      • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services.
    • Preliminary data relevant to the proposed clinical trial are required.
    • Pre-application is required; application submission is by invitation only.
    • Early-Career Investigator Partnering PI Option: Supports the development of young investigators pursuing or wishing to clinical trial.
    • The maximum allowable funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)
    • The maximum period of performance is years
    • Early-Career Investigator Partnering PI Option:
    • Maximum funding of $1,155,000 in direct costs (plus indirect costs)
    • Maximum period of performance is years

    Clinical Translational Award – Preapplication is due July 5, 2018

    • Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
    • Applications in the following areas are strongly encouraged:
      • Behavioral cognitive, and other non-pharmacological therapies.
      • Pharmacological, genetic, and other biological treatments in ASD.
      • Dissemination/Implementation of clinically validated interventions.
      • Therapies to alleviate conditions co-occurring with ASD (i.e., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures).
      • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
      • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
      • Improve diagnosis across the lifespan.
      • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services.
    • Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs)
    • The maximum period of performance is 3 years

    Idea Development Award – Preapplication is due July 5, 2018

    • Investigators at or above the level of Assistant Professor (or equivalent) or
    • Multiple PI Option: 
      Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 
    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
    • Applications in the following areas are strongly encouraged:
    •  Preliminary Behavioral cognitive, and other non-pharmacological therapies.
    • Pharmacological, genetic, and other biological treatments in ASD.
    • Dissemination/Implementation of clinically validated interventions.
    • Therapies to alleviate conditions co-occurring with ASD (i.e., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures).
    • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
    • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
    • Improve diagnosis across the lifespan.
    • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services.
    • Preliminary data are required.
    • Pre-application is required; application submission is by invitation only.
    • Multiple Principal Investigator (PI) Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
    • The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs)
    • For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $500,000 in direct costs (plus indirect costs)
    • The maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 22 May 2018 2:08 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriations Act provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

    The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.  Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

    ·        Develop treatments that improve outcomes for men with lethal prostate cancer

    ·        Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

    ·        Define the biology of lethal prostate cancer to reduce death

    ·        Improve the quality of life for survivors of prostate cancer

    http://cdmrp.army.mil/funding/pcrp

    Impact Award – Preproposal due July 19, 2018

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Preproposal is required; application submission is by invitation only.
    • Supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • The potential impact of the research is expected to be near-term, with the potential to transform the clinical management of prostate cancer within 5 years after the end of the award.
    • Proposed projects may include basic, translational, or clinical research, including small scale clinical trials.
    • Detailed transition plan to describe the pathway for moving the project’s findings to the next phase of development after the award is required.
    • Preliminary data to support feasibility are required.
    • Maximum funding of $750,000 for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Idea Development Award – Preproposal due July 6, 2018

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Or New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
    • Have the freedom to pursue individual aims without formal mentorship
    • Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award
    • Have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of terminal degree (excluding residency or family medical leave)
    • Preproposal is required; application submission is by invitation only.
    • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to eliminating death and enhancing the well-being of men with prostate cancer.
    • Emphasis is equally placed on Innovation and Impact.
    • Preliminary data are encouraged, but not required.
    • Clinical trials are not allowed.
    • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Maximum funding of $600K for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Physician Research Award – Letter of Intent due August 16, 2018

    • At the time of application submission, the PI must be either:
    • In the last year of an accredited graduate medical education program, either as a resident or fellow:
    • or
    • Within 3 years of having initiated an appointment as Instructor, Assistant Professor, or equivalent
    • Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
    • PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
    • PIs must have a designated mentor with an established research program in prostate cancer.
    • Institutions must provide at least 40% protection of PI’s time for research.
    • Projects that focus on basic research are highly encouraged.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • Maximum funding of $750,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.

    Early Investigator Research Award- Letter of Intent due August 16, 2018

    By March 31, 2019

    Postdoctoral Ph.D. or M.D. PIs:

    • Must have successfully defended a doctoral thesis or possess an M.D. degree
    • Have 3 years or less of postdoctoral research experience
    • Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
    • PIs must have a designated mentor who is an experienced prostate cancer researcher.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • Maximum funding of $200,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website.

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 16 May 2018 4:18 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The LRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 LRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018.  Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY18 LRP must address at least one of the three Focus Areas listed below:

    •           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

    •           Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.

    •           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

    http://cdmrp.army.mil/pubs/press/2018/18lrppreann

    Concept Award

    Investigators at all academic levels

    ·         Submission of a pre-application (Letter of Intent) is required prior to full application submission.

    ·         Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

    ·         Emphasis is on innovation

    ·         Clinical trials are not allowed

    • Preliminary data is not required

    ·         Maximum funding of $150,000 for total costs

    • Maximum period of performance is year

     

    Impact Award

    Investigators at or above Assistant Professor (or equivalent)

    ·         Submission of a pre-application (Letter of Intent) is required prior to full application submission.

    ·         Supports innovative, high-risk/high-reward research

    ·         Emphasis is on impact

    ·         Clinical trials are not allowed

    • Preliminary data is encouraged but not required

    ·         Maximum funding of $525,000 for total costs

    • Maximum period of performance is 3 years

    A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 16 May 2018 1:26 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriations Act provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY18 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Focus Areas:  The goal of the FY18 TSCRP is to fund exploratory, pioneering and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY18 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY18 Focus Areas:

    ·         Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency

    ·         Improving TSC disease models

    ·         Examining the clinical aspects of TSC, including phenotypic heterogeneity

    ·         Facilitating therapeutics, biomarkers, and clinical trials research

     

    http://cdmrp.army.mil/funding/tscrp

     

    Exploration - Hypothesis Development Award – Letter of Intent due July 11, 2018

    • ·         Investigators at all academic levels (or equivalent), including postdoctoral fellows

    ·         Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.

    ·         Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·         Preliminary data are not required.

    • ·         Clinical trials are not allowed.

    ·         Maximum funding of $100,000 for direct costs

    ·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

    • ·         Maximum period of performance is year

     

    Idea Development Award – Letter of Intent due July 11, 2018

    • ·         Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);
    • ·         or
    • ·         New Investigators:  Independent investigator at or below the level of Assistant Professor (or equivalent); or Established investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC.

    ·         Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.

    ·         Preliminary data are expected.

    ·         Clinical trials are not allowed.

    ·         New Investigator Option supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in TSC research.

    • o   Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed separately.

    ·         The maximum allowable funding for the entire period of performance is $450,000 in direct costs

    ·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

    • ·         Maximum period of performance is 3 years

     

    Clinical Translational Research Award – Letter of Intent due July 11, 2018

    • ·         Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·         Supports forward or reverse clinical/translational research studies that have the potential to improve the diagnosis, prognosis, or treatment of TSC.

    ·         Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 

    ·         Preclinical studies may be appropriate but must include a clinical component.

    ·         Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.

    ·         Should provide evidence for the reciprocal transfer of information between basic and clinical science.

    • ·         Preliminary data are required

    ·         The maximum allowable funding for the entire period of performance is $600,000 in direct costs.

    ·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    • ·         Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 16 May 2018 12:41 PM | Hawk Tran (Administrator)

    FY18 NFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY18 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY18 NFRP.  If the proposed research project does not address one of the FY18 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

    ·         Health services research

                        Evidence-based best clinical practices

                        Implementation and access to NF-specific health care

                        Utilization of technology and informatics

    ·         Heterogeneity of neurofibromas and other NF-related tumors

    ·         Nontumor manifestations

                        Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and underreported manifestations

    ·         Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

                        Transition from benign to malignant

    ·         Nutritional, environmental, and other modifiers of NF

    ·         Post-adolescent manifestations

    ·         Preclinical efficacy studies

    ·         Target identification, drug discovery, targeted and immunotherapies

    ·          

    http://cdmrp.army.mil/funding/nfrp

     

    Clinical Trial Award – Letter of Intent due 7/26/18

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Fund Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.
    • Funding must support a clinical trial and may not be used for preclinical studies.
    • Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

    ·         Maximum funding of $800,000 for direct costs (plus indirect costs)

    ·         Maximum funding of $1,000,000 for direct costs (plus indirect costs) for applications including a Collaborator

    • Maximum period of performance is years

     

    Exploration – Hypothesis Development Award – Letter of Intent due 7/26/18

    • All academic levels (or equivalent)

    ·         Fund the initial exploration of innovative, high-risk, high-gain and potentially. groundbreaking concepts in NF research

    ·         Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·         Preliminary and/or published data is encouraged but not required.

    • Clinical trials not allowed

    ·         Maximum funding of $100,000 for direct costs (plus indirect costs)

    • Maximum period of performance is 2 years

     

    Investigator-Initiated Research Award – Letter of Intent due July 26, 2018

    • Independent investigators at or above the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period throughout the entirety of the award
    • Fund highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.
    • ·         Optional Feature:  Applications that include a Qualified Collaborator who meets criteria identified in the announcement may apply for a higher level of funding.

    ·         Preliminary and/or published data required.

    • Clinical trials not allowed.

    ·         Maximum funding of $525,000 for direct costs (plus indirect costs)

    ·         Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including an Optional Qualified Collaborator

    • Maximum period of performance is 3 years

     

    New Investigator Award – Letter of Intent due July 26, 2018

    • Independent investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research

    ·         Support the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research

    ·         Experience in NF research is allowed, but not required

    ·         Preliminary and/or published data required

    • Clinical trials not allowed

    ·         Maximum funding of $450,000 for direct costs (plus indirect costs)

    • Maximum period of performance is 3 years

     

    Early Investigator Research Award – Letter of Intent due July 26, 2018

    ·         Postdoctoral Ph.D. or M.D. PIs:

    • Must have successfully defended a doctoral thesis or possess an M.D. degree and
    • Have at least 3 years and up to 6 years of consecutive postdoctoral fellowship

    ·         Supports research opportunities focused on NF for individuals in the early stages of their careers.

    • PIs must have a designated mentor who is an experienced NF researcher

    ·         Maximum funding of $200,000 for direct costs (plus indirect costs)

    • Maximum period of performance is 2 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@reBrap.org


  • 16 May 2018 10:07 AM | Hawk Tran (Administrator)

    The FY18 Defense Appropriations provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

     

    The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 DMDRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018. Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

     

    All applications for the FY18 DMDRP funding opportunities are required to address at least one of the following Focus Areas:

    • ·         Bone, cardiac, central nervous system (CNS), and/or gastrointestinal tract studies, including identifying mechanisms of pathology and therapeutic interventions
    • ·         Translational and clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve care and quality of life in areas such as:
    •         Cognitive function
    •         Endocrinology
    •         Gastrointestinal issues
    •         Immunology
    •         Orthopaedics
    •         Psychosocial issues
    •         Pulmonology (including sleep-focused studies)
    •         Skeletal muscle
    • ·         Assessment of clinical trial tools and outcome measures, such as:
    •         Discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers
    •         Novel clinical outcome assessment
    •         Patient-centered outcomes (e.g., quality of life, activities of daily living)
    •         Potential surrogate markers
    •         Secondary data analysis that helps to address clinical research tool validation and/or to understand natural history
    • ·         Extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (such as optimizing delivery to target tissues, including drug exposure, independent replication, and comparative studies)
    •  
    •  
    • http://cdmrp.army.mil/pubs/press/2018/18dmdrppreann
    •  
    • Investigator-Initiated Research Award
    • Principal Investigator:  Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

      Optional Nested Resident or Medical Student Trainee: Resident trainee must be enrolled in an accredited residency program.  Medical student trainee must be enrolled in a nationally accredited (or equivalent) medical school.  Trainees must be able to devote a minimum of 40% level of effort.
    • ·         Optional Interdisciplinary Collaborator:  Must be an independent investigator at or above the level of Assistant Professor (or equivalent), whose primary training, research, and experience is in a different field than the PI.  The collaborator is required to devote a minimum of 10% level of effort to this project.

    ·         Supports translational research that will have an impact on preserving and improving the function and quality of life, and extending the lifespan for all individuals with Duchenne.

    ·         Supports translational research that will accelerate the movement of promising new ideas in Duchenne research into clinical applications.

    ·         Optional Interdisciplinary Collaborator (OIC): Supports projects that include interdisciplinary collaborations that bring new perspectives from other disciplines and/or bring new investigators into the Duchenne field that through their collaboration the team can undertake conceptually and technically novel approaches that would be less likely to succeed if undertaken by a more narrowly focused group of investigators. Applications that include an OIC who meets criteria identified in the Program Announcement/Funding Opportunity may apply for a higher level of funding.

    ·         Clinical trials are allowed.

    • ·         Preliminary data are required.

    ·         Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·         Maximum period of performance is years.

    ·         Nested traineeship: Additional maximum of $50,000 for residents or $30,000 for medical students in direct costs (plus indirect costs) over a one-year period of performance.

    • ·         Optional Interdisciplinary Collaborator:  Additional maximum of $150,000 in direct costs over the 3-year period of performance.
    •  

    Career Development Award

    Principal Investigator:  Must be research (Ph.D.) or physician (M.D.) scientists at an early stage of their research careers with a minimum of 2 years post terminal degree (excluding medical residency or family medical leave), working to become independent investigators who exhibit a strong desire to pursue careers in Duchenne research.
    Mentor:  Must hold a position at or above the level of an Associate Professor (or equivalent).

    ·         Supports early-career investigators to conduct impactful research under the mentorship of an experienced muscular dystrophy researcher.

    ·         Clinical trials are not allowed.

    • Preliminary data are required.

    ·         Maximum funding of $275,000 for direct costs (plus indirect costs).

    • Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 15 May 2018 8:21 AM | Hawk Tran (Administrator)

    FY18 TBDRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. Pre-application and application deadlines will be available when the Program Announcements are

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Applications submitted to the FY18 TBDRP must address at least one of the following specific Focus Areas in Lyme disease and other tick-borne diseases:

    • Diagnosis
      • Accurate diagnostics for Lyme disease and co-infections and/or other tick-borne diseases
      • Biomarkers to identify tick-borne diseases or their products in humans
      • Diagnostic biomarkers for Lyme disease that distinguish between active infection and previous exposure, and/or monitor response to treatment
    • Pathogenesis
      • Immunological mechanisms of immune protection for Lyme disease or other tick-borne diseases
      • Complex biology of Lyme borrelia in the host (beyond in vitro studies), including its survival, evasion of the host immune system, and subversion of the effectiveness of antibiotics
      • Biomarkers that aid in exploring underlying mechanisms of persistent symptoms associated with Lyme disease
    • Prevention
      • Identification, validation, and/or improvement of tick-targeted prevention and control interventions
      • Human vaccines for tick-borne diseases
    • Treatment
      • Antibiotic combinations and/or therapeutic options for treating acute and persistent illness

    http://cdmrp.army.mil/funding/tbdrp

     

    Investigator-Initiated Research Award – Preproposal due June 25, 2018

    Independent investigators at or above the level of Associate Professor (or equivalent).

    • To fund highly rigorous, high-impact studies that have the potential to make important contributions to Lyme disease and other tick-borne disease research, patient care, and/or quality of life.
    • Applications should articulate both the short and long-term impact of the proposed research, including the potential impact of the research on reducing the public health burden of the disease being addressed.
    • Preliminary or published data to support feasibility are required.
    • Promotes any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial to establish proof-of-principle for further development in future studies; however, clinical trials are not allowed.
    • Maximum funding of $650K for direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

     

    Idea Award – Preproposal due June 25, 2018

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    • To fund conceptually innovative, high-risk/potentially high-reward research in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses.
    • Applications should articulate the qualities that make the research innovative (not merely an incremental advance), as well as the potential impact of the research on reducing thr public health burden of the disease being addressed.
    • Preliminary data that are relevant to the proposed research project are encouraged, but not required.
    • Clinical trials are not allowed.

    Maximum funding of $250K for direct costs (plus indirect costs).

    Maximum period of performance is 2 years.

     

    Career Development Award – Letter of Intent due June 25, 2018

    Principal Investigator (PI):
    Early-career research or physician scientists within 10 year of completing terminal degree (excluding time in residency or on family medical leave) at the time of submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded


    Mentor: Independent investigators at or above the level of Associate Professor (or equivalent); must have a proven funding and publication record in tick-borne disease research


    The PI and Mentor do not need to be located at the same organization.

    • To fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
    • Career Development Plan is required. Plan should be prepared with appropriate guidance from the Mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the PI will gain experience in tick-borne disease research.

    PI’s institution must demonstrate a commitment to the PI through a minimum of 30%    protected time for tick-borne disease research.

    • Preliminary data are not required; however, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.
    • Clinical trials are not allowed          
    • Maximum funding of $300K for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.
    •  

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the TBDRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 8 May 2018 11:44 AM | Hawk Tran (Administrator)

    FY18 PRMRP Program Announcements and General Application Instructions for the following award mechanism is posted on Grants.gov

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Congressionally Directed Topic Areas. All applications submitted to the PRMRP must address at least one of the FY18 PRMRP Congressionally directed topic areas.

    Topic Areas are as follows:

    • Acute Lung Injury
    • Antimicrobial Resistance
    • Arthritis
    • Burn Pit Exposure
    • Cardiomyopathy
    • Cerebellar Ataxia
    • Chronic Migraine and Post-Traumatic Headache
    • Chronic Pain Management
    • Congenital Heart Disease
    • Constrictive Bronchiolitis
    • Diabetes
    • Dystonia
    • Eating Disorders
    • Emerging Infectious Diseases
    • Endometriosis
    • Epidermolysis Bullosa
    • Focal Segmental Glomerulosclerosis
    • Fragile X Syndrome
    • Guillain-Barré Syndrome
    • Hepatitis B and C
    • Hereditary Angioedema
    • Hydrocephalus
    • Immunomonitoring of Intestinal Transplants
    • Inflammatory Bowel Diseases
    • Interstitial Cystitis
    • Lung Injury
    • Malaria
    • Metals Toxicology
    • Mitochondrial Disease
    • Musculoskeletal Disorders
    • Myotonic Dystrophy
    • Non-Opioid Pain Management
    • Nutrition Optimization
    • Pancreatitis
    • Pathogen-Inactivated Blood Products
    • Post-Traumatic Osteoarthritis
    • Pressure Ulcers
    • Pulmonary Fibrosis
    • Respiratory Health
    • Rett Syndrome
    • Rheumatoid Arthritis
    • Scleroderma
    • Sleep Disorders
    • Spinal Muscular Atrophy
    • Sustained-Release Drug Delivery
    • Tinnitus
    • Tuberculosis
    • Vascular Malformations
    • Women’s Heart Disease

    The mission of the PRMRP is to encourage, identify, and select military health-related research of exceptional scientific merit. Relevance to the healthcare needs of military Service members, Veterans, and their family members is a key feature of each FY18 PRMRP award mechanism.

    http://cdmrp.army.mil/funding/prmrp

    Clinical Trial Award

    • Assistant Professor level or above (or equivalent)
    • Preproposal submission is required; application submission is by invitation only.
    • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
    • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
    • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration by the PRMRP application submission deadline.
    • Funding limit not defined; requested funding must be appropriate for the scope of work proposed
    • Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government's single-entry portal,
    Grants.gov.. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-6182-5507
    help@eBrap.org


  • 7 May 2018 4:43 PM | Hawk Tran (Administrator)

    FY18 MSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Applications submitted to the FY18 MSRP must address at least one of the following Focus Areas:

    1) Obstacles to Remyelination and/or Obstacles to Axonal Protection in MS

    • Examples of acceptable studies include, but are not limited to, the roles of inhibitory factors, trophic factors, cell-cell interactions, and cell intrinsic factors.
    • Utilization and/or development of models that reflect the disease progression and translational approaches to evaluate benefit are encouraged.

    Note: Projects addressing the basic mechanisms of demyelination and neurodegeneration, inflammation or prevention of secondary injury following inflammation will not be considered for funding.

    (2) Correlates of Disease Activity and Progression in MS

    Studies may identify or validate correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

    • Correlates include clinical outcome measures, patient self-reported measures, and imaging and non-imaging biomarkers.
    • Examples of acceptable cohorts for study include controlled clinical trials, observational studies, and registries. Analyses may utilize existing clinical data and outcome measures, specimens, and/or imaging data.

    Note: The study must leverage pre-existing specimens and/or data that are available at the time of application submission; collection of additional data on the existing cohort is allowed.

    (3) Biology and Measurements of MS Symptoms (Exploration – Hypothesis Development Award ONLY!)

    • Symptoms may include pain, fatigue, cognitive dysfunction, visual impairment, motor impairment, impaired mobility, loss of bladder control, sexual dysfunction, depression, and anxiety.
    • Examples of acceptable studies include, but are not limited to, the following: development of measurements for future interventional studies to alleviate symptoms, rehabilitation, mechanisms underlying symptoms of MS, development and/or validation of outcome measures and tools for symptoms, and observational studies on the prevalence or significance of symptoms.

    Note: Studies of disease-modifying or regenerative therapies that secondarily impact symptoms will not be considered for funding.

    http://cdmrp.army.mil/funding/msrp

    Exploration - Hypothesis Development Award – Preproposal due June 26, 2018

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    • Pre-application submission is required; application submission is by invitation only.
    • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.
    • Preliminary data and/or published data not required.
    • Anticipated that budgets will not exceed $150,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 2 years
    • Clinical trials not allowed.

    Investigator-Initiated Research Award – Preproposal due June 26, 2018

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    • Pre-application submission is required; application submission is by invitation only.
    • Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.
    • Preliminary and/or published data required.
    • Anticipated that budgets will not exceed $600,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 3 years
    • Clinical trials not allowed.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism is also found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682/5507
    help@eBrap.org


  • 7 May 2018 2:22 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support the United States Medical Research Acquisition Activity.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018 Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    http://cdmrp.army.mil/pubs/press/2018/18kcrppreann

    Concept Award

    Investigators at all academic levels.

    ·      Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

    ·      Emphasis on innovation.

    ·      Funding for clinical trials is not allowed.

    ·      Preliminary data are not allowed.

    ·      Blinded review

    ·     Maximum funding of $75,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 1 year.

    Idea Development Award

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

    Early Career Investigators:

    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

    ·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

    ·      Preliminary data are required.

    ·      Innovation and Impact are the most important review criteria.

    ·      Funding for clinical trials is not allowed.

    ·      FY18 KCRP Areas of Emphasis are strongly encouraged.

    ·      Maximum funding of $400,000 in direct costs (plus indirect costs).

    ·      Period of performance is not to exceed 2 years.

    Physicians Research Award

    The PI must be a physician with clinical duties and/or responsibilities who, at the application submission deadline, is within 3 years of having initiated his/her first appointment as an Instructor, Assistant Professor, or equivalent

    ·      Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research.

    ·      This award emphasizes equally the quality of the proposed research project and the career development of the Principal Investigator (PI), which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.

    ·      Emphasis on multi-institutional/multi-disciplinary and collaboration.

    ·      Preliminary data are not required.

    ·      Funding for clinical trials is not allowed

    ·      Maximum funding of $200,000 in direct costs (plus indirect costs).

    ·      Period of performance is not to exceed 2 years.

    Technology Development Award

    Independent investigators at or above the level of Assistant Professor (or equivalent).

    ·      Supports emerging technologies to aid clinical and patient outcomes.

    ·      Preliminary data are required (need not be in kidney cancer).

    ·      Funding for clinical trials is not allowed.

    ·      Maximum funding of $300,000 in direct costs (plus indirect costs).

    ·      Period of performance is not to exceed 3 years.

    Translational Research Partnership

    Investigators at or above the level of Assistant Professor (or equivalent).

    ·      Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

    ·      Supports translational correlative studies.

    ·      Preliminary data are required.

    ·      Funding for clinical trials is not allowed.

    ·      Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software